跳至主要内容

Anti-drug Antibody Preparation

 Medicilon has rich experience in ADA development and has successfully delivered more than 100 projects. Medicilon can provide high-affinity and specific polyclonal anti-drug antibody development services with short development cycles and low costs.

  • Immunogenicity refers to the immune response generated by the immune system against drugs entering the human body. The immune response produces anti-drug antibodies (ADA) that specifically bind to drug molecules. In the process of drug development, especially for macromolecular drugs, small molecule and peptide drugs, and even related adjuvants, they may directly or indirectly cause a large immunogenic reactions. Mild reactions may lead to the termination of projects in the preclinical or clinical stages, resulting in the loss of early economic investments. Severe reactions may reduce drug efficacy, cause allergic reactions, and even pose a threat to life safety.
    According to current FDA guidelines, all serious immune responses, including acute hypersensitivity and neutralizing antibody responses, must be excluded during drug development. Therefore, ADA (Anti-Drug-Antibody)—effective detection in PK research, that is, systematic and scientific completion of ADA detection is an urgent issue in PK research.
    The evaluation of immunogenicity is mainly carried out by anti-drug antibody (anti-drug antibody, ADA) analysis method. In order to effectively evaluate the immunogenicity of antibody drugs in preclinical and clinical research, it is particularly important to develop reliable ADA assessment and detection methods.. Analytical techniques include ELISA, ECL, SPR, RIA, MSD, etc., and one or several combinations can be flexibly adopted. Currently, the most commonly used techniques are ECL and MSD.
    High-sensitivity and diverse polyclonal anti-drug antibodies can be used as a positive reference in immunogenicity studies, simulating the situation of ADA production in the human body. They can also specifically detect the level of antibody drugs in the body, making them important reagents for pharmacokinetic studies. Therefore, as essential tools in the development of antibody drugs, anti-drug antibodies are not only indispensable for clinical applications but also widely used in clinical stages.
    Medicilon has rich experience in ADA development and has successfully delivered more than 100 projects. Medicilon can provide high-affinity and specific polyclonal anti-drug antibody development services with short development cycles and low costs.
Development process
  • （1）Antigen preparation
    Antigen detection (1-2 days)Antigen reviewAntigen preparation (2 weeks)Conjugation or enzymatic cleavage of the full-length antibody drug provided by the client.
  • （2）Immunization and serum testing
    Immunization and serum titer testing (8 weeks)Blood collection before immunization, animal immunization, titer testing, final blood collection, provide immunization schedule and titer test report; titer meets ≥1:729,000       
  • （3）Antibody purification
    Antibody purification (2 weeks)Protein A purificationAntigen affinity chromatographyTotal human IgG de-cross-purified (optional)Other proteins to cross-purify (optional)       
  • （4）Antibody detection
    Antibody identification (1 week)SDS-PAGE purity analysis, UV concentration determinationTotal human IgG cross-reactivity;<2% cross-reactivity
  • （5）Delivery
    Delivery (12 weeks)Purified antibody, titer ≥1:243,000, quantity (optional)COAProject Development Detailed Report       

Advantage
  • Rich experience: More than 10 years of service development experience, one-to-one communication to customize projects, real-time feedback on experimental situations.Various types: Full-length antibodies, antibody fragments, small molecule drugs, peptide drugs, ADC drug conjugates, vaccines, etc.High quality:Guaranteed delivery sensitivity, cross-reactivity meeting regulatory requirements for PK/ADA detection antibodies.Various purification methods:Protein A/G, antigen affinity, Human IgG, isotype IgG, interfering protein, etc.

Case
  • Case 1-ADC Drug

    ADC drug- Serum titer.jpg


    Serum titer

    ADC drug-Antibody titer after purification.png


    Antibody titer after purification

  • Case 2-Antibody drug human IgG decrossover

    Antibody drug human IgG decrossover-Serum titer.png


    Serum titer

    Antibody drug human IgG decrossover-Antibody titer after purification.png


    Antibody titer after purification

标签：

评论

发表评论

此博客中的热门博文

In Vitro Enzyme Activity Assay

  Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+  in vitro  enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...
发表评论
阅读全文

Fluorescence Probes Synthesis

Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. Design and synthesis steps Fluorescent probes are tools used to detect, measure and analyze biomolecules, cells and tissues. They achieve these purposes by emitting and receiving fluorescent signals. Medicilon can complete the design and synthesis of fluorescent probes for biomolecules. Selection of target molecules and determination of target. Selection of fluorescent dyes. Design of molecular structure. Synthesize probe molecules. Testing the properties of probe molecules. Custom synthesis Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. After years of development, Medicilon's fluorescent probes and labeling platforms have accumulated rich experience...
发表评论
阅读全文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites   On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services
发表评论
阅读全文